§ 31-53-49. Requirements for Annual Report
The administrator shall prepare an annual report to include: Any policies established or revised pursuant to state and federal medical privacy laws, including the federal Health Insurance Portability and Accountability Act of 1996, P.L. 104-191, as amended; The number of requests for data and reports from the GAPCD, whether the request was submitted by a […]
§ 31-49-6. Donations
The council may solicit and accept donations, gifts, grants, property, or matching funds from any public or private source for the use of the council in performing its functions under this chapter. History. Code 1981, § 31-49-6 , enacted by Ga. L. 2014, p. 397, § 2/SB 352.
§ 31-51-1. Through 31-51-10
Reserved. Repealed pursuant to Code Section 31-51-10, which provided for the repeal of this chapter, effective July 1, 2020. Editor’s notes. This chapter consisted of Code Sections 31-51-1 through 31-51-10, relating to the creation of a low THC oil research program, and was based on Ga. L. 2015, p. 49, § 4-1/HB 1; Ga. L. […]
§ 31-52-1. Short Title
This chapter shall be known and may be cited as the “Georgia Right to Try Act.” History. Code 1981, § 31-52-1 , enacted by Ga. L. 2016, p. 345, § 1/HB 34.
§ 31-52-2. Legislative Findings
The General Assembly finds and declares that: The process of approval for investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the process often takes many years; Patients who have terminal illnesses do not have the luxury of […]
§ 31-52-3. Definitions
As used in this chapter, the term: “Eligible patient” means a person who meets the requirements of Code Section 31-52-4. “Investigational drug, biological product, or device” means a drug, biological product, or device which has successfully completed Phase I of a federal Food and Drug Administration approved clinical trial but has not yet been approved […]
§ 31-52-4. Eligibility Criteria
In order for a person to be considered an eligible patient to access an investigational drug, biological product, or device pursuant to this chapter, a physician must document in writing that the person: Has a terminal illness; Has, in consultation with the physician, considered all other treatment options currently approved by the federal Food and […]
§ 31-52-5. Written Informed Consent
Written informed consent shall, at a minimum, include the following: A description of the currently approved products and treatments for the terminal illness from which the patient suffers; An attestation that the patient concurs with his or her physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’s […]
§ 31-52-6. Manufacturers Permitted to Make Investigational Drugs, Biological Products, or Devices Available
A manufacturer of an investigational drug, biological product, or device may make available and an eligible patient may request access to the manufacturer’s investigational drug, biological product, or device pursuant to this chapter; provided, however, that nothing in this chapter shall be construed to require that a manufacturer make available an investigational drug, biological product, […]
§ 31-52-7. Coverage Under Health Benefit Plan Permitted but Not Required
A health benefit plan or governmental agency may provide coverage for the cost of any investigational drug, biological product, or device pursuant to this chapter; provided, however, that nothing in this chapter shall be construed to require a health benefit plan or governmental agency to provide coverage for the cost of any investigational drug, biological […]